Section 1 of 6
Terms and abbreviations
1 evidence topic · 0 sources
| Abbreviation | Term |
|---|---|
| 24(S)-HC, 24(S)-OHC, 24(S)OHC, 24OHC | 24(S)-hydroxycholesterol |
| 2D-LC-IF-MS/MS | Two-dimensional liquid chromatography in-source fragmentation tandem mass spectrometry |
| 4DNPCCSS, 4DNPCSS | 4-domain composite NPC Clinical Severity Scale |
| 5DNPCCSS, 5DNPCCS | 5-domain NPC Clinical Severity Scale |
| 7-KC | 7-ketocholesterol |
| ABC | Adaptive Behavior Composite (Vineland-II) |
| ABR | Auditory brainstem response |
| ACMG | American College of Medical Genetics and Genomics |
| ADLs | Activities of daily living |
| AE, AEs | Adverse event, adverse events |
| AHFS | American Hospital Formulary Service |
| ANCOVA | Analysis of covariance |
| ANO | Age at neurological onset |
| ASMD | Acid sphingomyelinase deficiency |
| ASO | Antisense oligonucleotide |
| ATC | Anatomical Therapeutic Chemical classification |
| AUC | Area under the curve |
| AUC0-last | Area under the plasma concentration-time curve from time 0 to the last measurable concentration |
| AUC8–72 | Area under the curve from 8 to 72 hours after dosing |
| AZ-3102 | Development code for nizubaglustat |
| BCRP | Breast cancer resistance protein |
| Big4 | Big Four federal price (Department of Veterans Affairs, Department of Defense, Public Health Service, and Coast Guard) |
| BSEP | Bile salt export pump |
| BTD | Breakthrough Therapy Designation |
| BUN | Blood urea nitrogen |
| C-triol | Cholestane-3β,5α,6β-triol |
| CA | California |
| CAD | Canadian dollars |
| CAP | Capsule |
| CBMC | Cerebellomedullary cistern |
| CCO | Coordinated Care Organization |
| CFR | Code of Federal Regulations |
| CGI-S | Clinical Global Impression of Severity |
| CGIC | Clinical Global Impression of Change |
| CHMP | Committee for Medicinal Products for Human Use |
| CHU | Centre Hospitalier Universitaire (university hospital center) |
| CI | Confidence interval |
| CI-CS | Clinical Impression of Change in Severity |
| CLEAR | Coordinated lysosomal expression and regulation |
| Cmax | Maximum concentration |
| CMS | Centers for Medicare & Medicaid Services |
| CNS | Central nervous system |
| CPT | Current Procedural Terminology |
| CRADA | Cooperative research and development agreement |
| CRISPR/Cas9 | Clustered regularly interspaced short palindromic repeats and CRISPR-associated protein 9 |
| CRL | Complete Response Letter |
| CSF | Cerebrospinal fluid |
| CT | Computed tomography |
| CTCAE | Common Terminology Criteria for Adverse Events |
| CV | Coefficient of variation |
| CYP | Cytochrome P450 |
| DB | Double-blind |
| dB HL | Decibels hearing level |
| DBS | Dried blood spot |
| DC | District of Columbia |
| DDA | Developmental Disabilities Administration |
| DNA | Deoxyribonucleic acid |
| DoD | Department of Defense |
| DSC | Dose selection committee |
| EA | Each (unit of reimbursement) |
| EAP, EAPs | Expanded Access Program, Expanded Access Programs |
| eGFR | Estimated glomerular filtration rate |
| EI | Early infantile (neurological onset form) |
| EI-NP-C | Early infantile Niemann-Pick disease type C |
| EMA | European Medicines Agency |
| EP | Extension phase |
| EPAR | European public assessment report |
| EQ-5D-3L | EuroQol 5-Dimension 3-Level questionnaire |
| ER | Endoplasmic reticulum |
| ERT | Enzyme replacement therapy |
| EU | European Union |
| FABP3 | Fatty acid binding protein 3 |
| FAM | Family Access Manager |
| FD&C Act, FDCA | Federal Food, Drug, and Cosmetic Act |
| FDA | Food and Drug Administration |
| FDR | False discovery rate |
| FEES | Fiberoptic endoscopic evaluation of swallowing |
| FFS | Fee-for-service |
| fSARA | Functional Scale for the Assessment and Rating of Ataxia |
| FSIQ | Full-Scale IQ |
| FSS | Federal Supply Schedule |
| GD | Gestation day |
| GeMDAC | Genetic Metabolic Diseases Advisory Committee |
| GFR | Glomerular filtration rate |
| HCC | Hepatocellular carcinoma |
| HCPCS | Healthcare Common Procedure Coding System |
| HCPs | Health care professionals |
| HDPE | High-density polyethylene |
| HGNC | HUGO Gene Nomenclature Committee |
| HPβCD, HP-β-CD, HPBCD, HPB-CD, HP-Beta-CD, HPßCD, 2HPβCD | 2-hydroxypropyl-beta-cyclodextrin |
| HR | Hazard ratio |
| HRQOL, HRQoL | Health-related quality of life |
| HSCT | Hematopoietic stem cell transplantation |
| HSEM, HSEM-alpha | Horizontal saccadic eye movement (velocity) |
| HSP70 | Heat shock protein 70 |
| I-NPC | Infantile-onset Niemann-Pick disease type C (neurological onset before 6 years of age) |
| ICC, ICCs | Intraclass correlation coefficient, intraclass correlation coefficients |
| ICD-10-CM | International Classification of Diseases, Tenth Revision, Clinical Modification |
| ICER | Institute for Clinical and Economic Review |
| ICV | Intracerebroventricular |
| ID | Intellectually disabled |
| IND | Investigational new drug (application) |
| INPDA | International Niemann-Pick Disease Alliance |
| INPDR | International Niemann-Pick Disease Registry |
| IPR&D | In-process research and development |
| IQ | Intelligence quotient |
| IQR | Interquartile range |
| IRB | Institutional review board |
| IT | Intrathecal |
| IT-HPBCD | Intrathecal 2-hydroxypropyl-beta-cyclodextrin |
| ITC | Isothermal titration calorimetry |
| IV | Intravenous |
| KM | Kaplan-Meier |
| LLC | Limited liability company |
| LP, LPs | Lumbar puncture, lumbar punctures |
| LS | Least squares |
| LTx | Liver transplantation |
| lyso-SM | Lysosphingomyelin |
| MATE | Multidrug and toxin extrusion protein |
| MBSImp | Modified Barium Swallowing Impairment Scale |
| MD | Maryland |
| MDT | Multidisciplinary team |
| MHRA | Medicines and Healthcare products Regulatory Agency |
| mITT | Modified intent-to-treat |
| MMRM | Mixed model repeated measures |
| MNAR | Missing not at random |
| MRHD | Maximum recommended human dose |
| N/A | Not applicable |
| NADAC | National Average Drug Acquisition Cost |
| NALL | N-acetyl-L-leucine |
| NCATS | National Center for Advancing Translational Sciences |
| NCI | National Cancer Institute |
| NDA | New Drug Application |
| NDC | National Drug Code |
| NE | Not estimable |
| NfL | Neurofilament light chain |
| NHS | National Health Service |
| NHx | Natural history |
| NICE | National Institute for Health and Care Excellence |
| NICHD | Eunice Kennedy Shriver National Institute of Child Health and Human Development |
| NIH | National Institutes of Health |
| NIH CC | National Institutes of Health Clinical Center |
| NIH-PAS | National Institutes of Health Penetration-Aspiration Scale |
| NLGase | Non-lysosomal neutral glucosylceramidase |
| NP-C | Niemann-Pick disease type C |
| NPC | Niemann-Pick disease type C |
| NPC-002 | Protocol number of the phase 2/3 trial of arimoclomol |
| NPC-CSS-17 | 17-domain NPC Clinical Severity Scale |
| NPC-SI | NPC Suspicion Index |
| NPC-SS | NPC Severity Scale |
| NPC1, NPC-1 | Niemann-Pick disease type C1; NPC intracellular cholesterol transporter 1 (gene and protein) |
| NPC2 | Niemann-Pick disease type C2; NPC intracellular cholesterol transporter 2 (gene and protein) |
| NPCCSS, NPC-CSS | NPC Clinical Severity Scale |
| NPCQLQ-A | NPC quality-of-life questionnaire for adults |
| NPCQLQ-C | NPC quality-of-life questionnaire for children |
| NPD | Niemann-Pick disease |
| NSE | Neuron-specific enolase |
| NSS | NPC Neurological Severity Score |
| NVIQ | Nonverbal/Perceptual Reasoning IQ |
| NYU | New York University |
| OAEs | Otoacoustic emissions |
| OAT | Organic anion transporter |
| OATP | Organic anion transporting polypeptide |
| OCT | Organic cation transporter |
| ODB | Ontario Drug Benefit |
| OHCs | Outer hair cells |
| OHP | Oregon Health Plan |
| OL | Oligodendrocyte |
| OLE | Open-label extension |
| OLEX | Open-label extension (program) |
| OMIM | Online Mendelian Inheritance in Man |
| OPPS | Outpatient Prospective Payment System |
| OR | Odds ratio |
| OS | Overall survival |
| P-gp, P-gP | P-glycoprotein |
| PA | Prior authorization |
| PAP | Patient Assistance Program |
| PAS | Penetration-Aspiration Scale |
| PBC | Public benefit corporation |
| PDL | Preferred Drug List |
| PDUFA | Prescription Drug User Fee Act |
| PK | Pharmacokinetics |
| PP | Per-protocol |
| PPCS | N-palmitoyl-O-phosphocholineserine |
| PRV | Priority review voucher |
| Q1, Q3 | First quartile, third quartile (in company timelines, first and third calendar quarter) |
| Q2W | Every 2 weeks |
| Q4W | Every 4 weeks |
| QALYs | Quality-adjusted life years |
| QoL, QOL | Quality of life |
| R4DNPCCSS | Rescored 4-domain NPC Clinical Severity Scale |
| RAND-36 | RAND 36-Item Health Survey |
| RCT | Randomized controlled trial |
| RH | Relative humidity |
| RP-UPLC-MS/MS | Reversed-phase ultra-performance liquid chromatography tandem mass spectrometry |
| RUMC | Rush University Medical Center |
| SAE, SAEs | Serious adverse event, serious adverse events |
| SARA | Scale for the Assessment and Rating of Ataxia |
| SAS | Statistical Analysis System (software) |
| SC | South Carolina |
| SCT | Safety Concern Threshold |
| SD | Standard deviation |
| SE | Standard error |
| SEM | Standard error of the mean |
| SMAC | State Maximum Allowable Cost |
| SMC | Scottish Medicines Consortium |
| sNDA | Supplemental New Drug Application |
| SRT | Substrate reduction therapy |
| t1/2 | Elimination half-life |
| TEAE, TEAEs | Treatment-emergent adverse event, treatment-emergent adverse events |
| TFE3 | Transcription factor E3 |
| TFEB | Transcription factor EB |
| Tmax | Time to peak plasma concentration |
| TX | Texas |
| UCLA | University of California, Los Angeles |
| UK | United Kingdom |
| US, U.S., USA | United States |
| USD | United States dollars |
| USP | United States Pharmacopeia |
| VA | Veterans Affairs |
| Vdss | Volume of distribution at steady state |
| VFSS | Videofluoroscopic swallow study |
| Vineland-II | Vineland Adaptive Behavior Scales, Second Edition |
| VIQ | Verbal IQ |
| VSGP | Vertical supranuclear gaze palsy |
| VSSP | Vertical supranuclear saccadic palsy |
| VTS-270 | Development code for adrabetadex (Vtesse) |
| VTS-270-001 | Protocol number of the open-label trial of VTS-270 (NCT03643562) |
| VTS-270-302 | Protocol number of the 2-participant open-label study of adrabetadex in Costa Rica |
| VTS301, VTS-301 | Protocol number of the phase 2b/3 trial of VTS-270 (Parts A and B, NCT02534844; Part C, NCT04958642) |
| WAC | Wholesale acquisition cost |
| WRAML | Wide Range Assessment of Memory and Learning |
| YODA | Yale University Open Data Access (Project) |